Rivas, A.; Delyon, J.; Martineau, A.; Blanc, E.; Allayous, C.; Da Meda, L.; Merlet, P.; Lebbé, C.; Baroudjian, B.; Vercellino, L.
18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers 2022, 14, 3190.
https://doi.org/10.3390/cancers14133190
AMA Style
Rivas A, Delyon J, Martineau A, Blanc E, Allayous C, Da Meda L, Merlet P, Lebbé C, Baroudjian B, Vercellino L.
18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers. 2022; 14(13):3190.
https://doi.org/10.3390/cancers14133190
Chicago/Turabian Style
Rivas, Alexia, Julie Delyon, Antoine Martineau, Estelle Blanc, Clara Allayous, Laetitia Da Meda, Pascal Merlet, Céleste Lebbé, Barouyr Baroudjian, and Laetitia Vercellino.
2022. "18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors" Cancers 14, no. 13: 3190.
https://doi.org/10.3390/cancers14133190
APA Style
Rivas, A., Delyon, J., Martineau, A., Blanc, E., Allayous, C., Da Meda, L., Merlet, P., Lebbé, C., Baroudjian, B., & Vercellino, L.
(2022). 18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers, 14(13), 3190.
https://doi.org/10.3390/cancers14133190
